(Q36872933)

16 August 2017

1 reference

title

Pre-exposure prophylaxis for HIV infection: what if it works? (English)

1 reference

pre-exposure prophylaxis against HIV

16 August 2017

main subject

1 reference

3

Harold W Jaffe

1 reference

16 August 2017

Lynn A Paxton

1

1 reference

16 August 2017

Tony Hope

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

370

1 reference

16 August 2017

issue

9581

1 reference

16 August 2017

page(s)

89-93

1 reference

Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

A tale of two futures: HIV and antiretroviral therapy in San Francisco.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Modelling the impact of antiretroviral use in resource-poor settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

Shifts in condom use following microbicide introduction: should we be concerned?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961053-8

7 January 2021

10.1016/S0140-6736(07)61053-8

Identifiers

DOI

1 reference

16 August 2017

1 reference